GENPHARMASEC
LIMITED

Date: 03.11.2026

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 531592

Subject: Outcome of the Meeting of Board of Directors held on Tuesday, 03rd November, 2026.

Dear Sir/Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of the Company at its meeting held on today, i.e Tuesday, 03rd November, 2026, have inter alia, other matters:

1. Considered and approved the Un-audited Standalone & Consolidated Financial Results of the Company along with Limited Review Report of the Statutory Auditor for the quarter and half year ended September 30, 2026.

2. Considered and approved the Disinvestment/Sale/Disposal of entire Equity stake held in its wholly owned subsidiary company viz., Clinigenome India Private Limited.

   Clinigenome India Private Limited is not a material subsidiary of the company. Upon Completion of the aforesaid sale, Clinigenome India Private Limited will cease to be a wholly owned subsidiary of the Company.

   Details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure-A.

3. Considered and approved the Resignation of Mr. Hardik Makwana, Company Secretary and Compliance Officer of the Company, from his position with effect from close of business hours on November 16, 2026. (a copy of the resignation letter is attached herewith).

   Details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure-B.

104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.
compliance@genpharmasec.com
info@genpharmasec.com
+91-86555 50242
www.genpharmasec.com

GENPHARMASEC
LIMITED

We further inform you that the Board Meeting commenced at 04:30 p.m. today and concluded at 05:15 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For Genpharmasec Limited

SOHAN CHATURVEDI
Digitally signed by SOHAN CHATURVEDI
Date: 2026.11.03 17:17:51 +05'30'

GENPHARMASEC LIMITED

Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728

Encl:
1. Un-Audited Standalone & Consolidated Financial Results for the quarter & half year ended September 30, 2026.
2. Limited Review Report of the Auditor.
3. Resignation letter.

104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.
compliance@genpharmasec.com
info@genpharmasec.com
+91-86555 50242
www.genpharmasec.com

GENPHARMASEC
LIMITED

Annexure-A

<table>
<tr><th>Sr No.</th><th>Particulars</th><th colspan="3">Details</th></tr>
<tr><td rowspan="4">1.</td><td rowspan="4">The amount and percentage of turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year.</td><td colspan="3">Name of the subsidiary:
Clinigenome India Private Limited</td></tr>
<tr><td>Particulars</td><td>Rs. In Lakhs</td><td>%</td></tr>
<tr><td>Turnover</td><td>100.47</td><td>0.72 % of the consolidated turnover</td></tr>
<tr><td>Net Worth</td><td>(154.41)</td><td>2.35% of the consolidated turnover</td></tr>
<tr><td>2.</td><td>Date on which the agreement for sale has been entered.</td><td colspan="3">Yet to be entered.
The Company will intimate the Exchanges upon signing of agreement.</td></tr>
<tr><td>3.</td><td>The expected date of completion of sale/disposal.</td><td colspan="3">The proposed sale transaction is expected to be completed on or before March 31, 2027, or such other date as may be determined and approved by the Board of Directors of the Company.</td></tr>
<tr><td>4.</td><td>Consideration received from such sale/disposal.</td><td colspan="3">The consideration for the proposed sale shall be such amount as may be determined, negotiated and approved by the Board of Directors of the Company.</td></tr>
<tr><td>5.</td><td>Brief details of Buyers and whether any of the buyers belong to the Promoter or the Promoter Group/ Group Companies. If yes, details thereof.</td><td colspan="3">The Board of Directors of the Company has identified Micro Genomics India Private Limited as the proposed buyer for the sale.
The proposed buyer does not belong to the Promoter or Promoter Group or Group Companies of the Company.</td></tr>
<tr><td>6.</td><td>Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length.</td><td colspan="3">Not Applicable</td></tr>
<tr><td>7.</td><td>Whether the sale, lease or disposal of the undertaking is outside the Scheme of Arrangement? If yes, details of the same including Compliance under regulation 37 A of the LODR Regulations.</td><td colspan="3">Not Applicable</td></tr>
<tr><td>8.</td><td>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.</td><td colspan="3">Not Applicable</td></tr>
</table>

104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.
compliance@genpharmasec.com
info@genpharmasec.com
+91-86555 50242
www.genpharmasec.com

GENPHARMASEC
LIMITED

Annexure-B

Sr. No.	Particulars	Details
1.	Reason for change viz. ~~appointment~~, ~~re-appointment~~, resignation, ~~removal~~, ~~death~~ or ~~otherwise~~;	Resignation Due to pursue of other professional opportunities outside the Organization.
2.	Date of ~~appointment/reappointment~~/cessation (as applicable) & ~~term of appointment/re-appointment;~~	Cessation with effective from the close of Business hours on November 16, 2026.
3.	Brief Profile (in case of appointment);	Not Applicable
4.	Disclosure of Relationships between Directors (in case of appointment of a director);	Not Applicable

104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.
compliance@genpharmasec.com
info@genpharmasec.com
+91-86555 50242
www.genpharmasec.com

BILIMORIA MEHTA & CO.
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of Genpharmasec Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Genpharmasec Limited ('the Company') for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W





Aakash Mehta
Partner
Membership no. 165824
UDIN: 26165824JQNMRS6039
Place of Signature: Mumbai
Date: November 03, 2026

GENPHARMASEC LIMITED

Corporate Identity Number (CIN): L24231MH1992PLC323914

Statement of Standalone unaudited financial results for the Quarter and Half year ended September 30, 2026

(All amounts are in INR Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	5,083.08	4,478.44	3,156.37	9,561.52	4,367.68	13,134.94
II	Other Income	166.47	97.06	100.02	263.53	182.26	486.94
III	**Total Income (I + II)**	**5,249.55**	**4,575.50**	**3,256.39**	**9,825.05**	**4,549.94**	**13,621.88**
IV	**Expenses**						
	Purchase of Stock-in-Trade	4,465.49	4,530.97	3,977.54	8,996.45	5,100.10	13,139.94
	Changes in Inventories of Finished goods and Stock-in-Trade	348.40	(249.05)	(925.84)	99.35	(995.69)	(533.38)
	Employee benefit expense	25.58	24.21	18.82	49.78	40.01	97.27
	Finance Costs	15.74	12.70	7.86	28.44	15.53	59.36
	Depreciation and Amortization Expense	9.93	9.77	4.49	19.70	8.80	25.60
	Other Expenses	78.19	37.19	35.46	115.38	72.53	189.39
	Total Expenses (IV)	**4,943.32**	**4,365.78**	**3,118.32**	**9,309.10**	**4,241.30**	**12,978.19**
V	**Profit before tax (III - IV)**	**306.23**	**209.72**	**138.06**	**515.95**	**308.65**	**643.69**
VI	**Tax expense:**						
	(1) Current tax	60.18	51.66	60.94	111.83	77.75	152.32
	(2) Deferred Tax	(11.30)	1.10	(4.47)	(10.19)	(6.61)	(17.73)
	(3) Prior Period Tax	-	-	-	-	-	(35.86)
	Total Tax Expense	**48.88**	**52.76**	**56.47**	**101.64**	**71.13**	**98.72**
VII	**Profit for the period (V-VI)**	**257.35**	**156.96**	**81.59**	**414.31**	**237.51**	**544.96**
VIII	**Other Comprehensive Income/(Loss)**						
	(i) Items that will not be reclassified to Profit and Loss						
	(a) Remeasurement of post employment defined benefit plans	-	-	-	-	-	0.52
	(b) Income tax effect on above	-	-	-	-	-	(0.13)
	(c) Equity instrument through other comprehensive income	(34.28)	16.78	(18.07)	(17.50)	(3.81)	(50.68)
	(d) Income tax effect on above	-	-	-	-	-	-
	Sub-total	**(34.28)**	**16.78**	**(18.07)**	**(17.50)**	**(3.81)**	**(50.29)**
IX	**Total Comprehensive Income/(Loss) for the year (VII + VIII) (Comprising profit and other comprehensive income for the year)**	**223.07**	**173.74**	**63.52**	**396.81**	**233.70**	**494.67**
	Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	**5,537.20**	**5,537.20**	**5,537.20**	**5,537.20**	**5,537.20**	**5,537.20**
X	**Earning per equity share**						
	(1) Basic	**0.05**	**0.03**	**0.01**	**0.07**	**0.04**	**0.10**
	(2) Diluted	**0.05**	**0.03**	**0.01**	**0.07**	**0.04**	**0.10**

Notes:

1.The unaudited financial results of the Company for the quarter and half year ended September 30, 2026 have been prepared in accordance with the Indian Accounting Standards("Indian Accounting Standards("Ind As") as Prescribed under section 133 of the Companies Act, 2013 as amended.

2.The Company is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108 'Operating Segment'. Accordingly, no separate segment information has been provided.

3.The unaudited financial results of the Company for the quarter and half year ended September 30, 2026 have been reviewed by the audit committee on November 03, 2026 and thereafter Board of directors at their meeting held on November 03, 2026.

4. The results for the quarter ended September 30, 2026 are the balancing figures between in respect of the half year ended results as on September 30, 2026 and the published unaudited financial results for the quarter ended June 30, 2026. Similarly, The results for the quarter ended September 30, 2025 are the balancing figures between in respect of the half year ended results as on September 30, 2025 and the published unaudited financial results for the quarter ended June 30, 2025.

5. Investment in subsidiary classified as held for sale

During the meeting held on November 03, 2026, the Board of Directors approved a plan to sell its entire equity stake in its subsidiary, Clinigenome India Private Limited. The sale is expected to be completed within twelve months from the date of classification.

Accordingly, in accordance with Ind AS 105, Non-current Assets Held for Sale and Discontinued Operations, the Company's investment in Clinigenome India Private Limited, which is carried at cost in accordance with Ind AS 27, has been classified as "Non-current assets held for sale" in the standalone financial results as at September 30, 2026, and is measured at the lower of its carrying amount and fair value less costs to sell. No impairment loss has been recognised upon such classification for the period ended September 30, 2026.

6.Previous period figures have been regrouped/reclassified, as considered necessary, to conform with current period presentation, wherever applicable.

For and on behalf of the Board of Directors of
Genpharmasec Limited

Soham

Soham Chaturvedi
(Whole Time Director & CFO)
DIN:09629728

GENPHARMASEC LIMITED

Place: Mumbai
Date : November 03, 2026

GENPHARMASEC LIMITED

Corporate Identity Number (CIN): L24231MH1992PLC323914

Statement of Standalone Assets and Liabilities

(All amounts are in INR Lakhs, unless otherwise stated)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipments	10.06	10.77
(b) Right of Use Assets	84.77	101.91
(c) Financial Assets		
(i) Investments	2,030.12	2,167.02
(ii) Loans	3,096.96	2,456.98
(iii) Other Financial Assets	409.91	59.56
(d) Deferred Tax Assets (Net)	41.37	31.17
(e) Other Non-Current Assets	1.41	1.59
Total Non-Current Assets	**5,674.60**	**4,829.01**
(2) Current Assets		
(a) Inventories	1,158.46	1,257.81
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	2,616.58	2,801.57
(iii) Cash and Cash Equivalents	254.17	79.13
(iv) Bank Balances Other Than Cash And Cash Equivalents	250.00	850.00
(v) Loans	148.61	640.61
(vi) Other Financial Asset	528.41	411.97
(c) Other Current Assets	126.81	135.98
Total Current Assets	**5,083.05**	**6,177.08**
Assets Held for Sale	**200.23**	-
Total Assets	**10,957.88**	**11,006.09**
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	5,537.20	5,537.20
(b) Other Equity	2,009.27	1,612.46
Total Equity	**7,546.47**	**7,149.66**
LIABILITIES		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	521.96	386.96
(ii) Lease Liabilities	64.79	77.43
(iii) Provisions	7.54	6.34
Total Non-Current Liabilities	**594.29**	**470.73**
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	899.60	-
(ii) Lease Liabilities	25.19	28.03
(iii) Trade Payables		
(A)Total outstanding dues of micro and small enterprises	27.22	26.90
(B)Total outstanding dues of creditors other than micro and small enterprises	1,484.01	2,985.68
(iv) Other Financial Liabilities	92.33	76.24
(b) Short Term Provisions	1.13	1.13
(c) Current Tax Liabilities	107.38	91.22
(d) Other Current Liabilities	180.27	176.50
Total Current Liabilities	**2,817.12**	**3,385.69**
Total Equity and Liabilities	**10,957.88**	**11,006.09**

For and on behalf of the Board of Directors of
Genpharmasec Limited



Sohan Chaturvedi
(Whole Time Director & CFO)
DIN:09629728

Place: Mumbai
Date : November 03, 2026

GENPHARMASEC LIMITED
Corporate Identity Number (CIN): L24231MH1992PLC323914
Statement of Standalone Unaudited Cash Flow
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	For the period ended September 30, 2026 (Unaudited)	For the period ended September 30, 2025 (Unaudited)
A. Cash Flow from Operating Activities		
Net Profit Before Tax	515.95	308.65
Adjustment for :		
Depreciation and Amortization	19.70	8.61
Expected Credit Loss	3.74	25.66
Interest Income other than interest on Bank Deposits	(165.15)	(171.36)
Interest on Bank Deposits	(38.88)	-
Finance Cost other than interest on lease liabilities	24.37	14.25
Interest on lease liabilities	4.07	1.28
Dividend Income	(0.01)	(0.01)
Balances Written Off	32.35	-
Provision for Gratuity	1.20	-
Creditors Written Back	(32.34)	-
Deferred Rent Income	(0.39)	-
Operating Profit before Working Capital Changes	**364.60**	**187.07**
Changes in Inventories	99.35	(995.69)
Changes in Trade Receivables	148.91	(1,151.58)
Changes in Other Non Current & Current Financial Assets	(87.58)	(7.55)
Changes in Other Non Current and Current Assets	8.95	(168.40)
Changes in Trade Payables	(1,469.01)	2,995.70
Changes in Other Financial Liabilities	16.08	1.30
Changes in Other Current Liabilities	3.77	109.50
	(914.94)	**970.36**
Income Tax Paid (Net)	(94.43)	(13.04)
A. Net cash flow (used in)/from operating activities	**(1,009.36)**	**957.32**
B. Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment	(1.45)	(1.14)
Investments made	-	(120.16)
Fixed Asset Deposit created	-	(856.03)
Loans given	(148.39)	(48.56)
Receipt against loan given	83.50	0.42
Interest Received	10.06	17.33
Dividend Received	0.01	0.01
B. Net cash used in investing activities	**(56.27)**	**(1,008.13)**
C. Cash Flow from Financing Activities		
Proceeds from Short term borrowings (Net)	899.60	(10.44)
Proceeds from Long Term Borrowings	135.00	-
Payment of Lease liability	(19.56)	(8.34)
Finance charges paid	(24.37)	(14.25)
C. Net cash used in financing activities	**990.67**	**(33.02)**
D. Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	**(74.96)**	**(83.83)**
E. Opening Cash & Cash Equivalents (Cash and Bank Balances)	79.13	514.37
Add: Fixed Deposit having maturity less than three months	250.00	-
Closing Cash & Cash Equivalents (D+E)	**254.17**	**430.54**

Notes
The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of Cash Flow

For and on behalf of the Board of Directors of
Genpharmasec Limited



Sohan Chaturvedi
(Whole Time Director & CFO)
DIN:09629728

Place: Mumbai
Date : November 03, 2026

BILIMORIA MEHTA & CO.
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of Genpharmasec Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results ('the Statement') of Genpharmasec Limited ('the Holding Company') and its Subsidiaries (the Holding Company and its Subsidiaries together referred to as the "the Group") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 attached herewith being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the entities mentioned in Annexure I

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed above as stated in paragraph 3 and based on the consideration of the review reports of the other auditors referred to in paragraph 6 & 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of two subsidiaries, whose unaudited interim financial results include total assets of Rs. 5,092.01 lakhs as at September 30, 2026, total revenue of Rs. 3,975.33, total net loss after tax of Rs. 216.54 lakhs and total comprehensive loss of Rs. 216.54 lakhs for the period ended September 30, 2026 as considered in the Statement, which have been reviewed by their respective independent auditors.

   The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. One of the subsidiaries is located outside India, and its financial statements and other financial information have been prepared in accordance with the accounting principles generally accepted in the respective country and audited by its auditor in accordance with the auditing standards generally accepted in that country. The Company's management has converted the financial statements of such subsidiary from the accounting principles generally accepted in that country to the accounting principles generally accepted in India. These financial statements and other financial information, including the conversion adjustments made by the management, have been reviewed by the other auditors. Our opinion, insofar as it relates to the balances and affairs of this subsidiary located outside India, is based on the report of the other auditors and the conversion adjustments prepared by the Company's management and reviewed by the other auditors.

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

8. Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W



Aakash Mehta
Partner
Membership no. 165824
UDIN: 26165824KVGMKU1889
Place of Signature: Mumbai
Date: November 03, 2026

Annexure -1

Sr. No	Particulars	Status
1	Clinigenome India Private Limited	Subsidiary
2	Genpharmasec Middle East DMCC	Subsidiary
3	Derren Healthcare Private Limited	Subsidiary



GENPHARMASEC LIMITED
CIN: L24231MH1992PLC323914
Statement of Consolidated unaudited financial results for the Quarter and Half year ended September 30, 2026
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Sr. No.	Particulars	Quarter Ended			Half Year ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	8,565.82	4,971.03	3,263.71	13,536.85	4,468.04	13,993.77
II	Other Income	106.03	37.30	46.48	143.34	115.95	315.70
III	**Total Income (I + II)**	8,671.85	5,008.34	3,310.19	13,680.19	4,583.99	14,309.47
IV	**Expenses:**						
	(a) Cost of materials consumed	169.29	105.90	88.77	275.19	101.63	284.02
	(b) Purchase of Stock-in-Trade	7,462.91	4,748.43	3,977.54	12,211.33	5,100.10	13,139.94
	(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	333.82	(259.90)	(1,028.69)	73.92	(1,133.28)	(565.96)
	(d) Employee benefit expense	112.36	110.79	119.72	223.14	154.68	387.00
	(e) Financial costs	44.18	39.92	22.52	84.09	34.78	124.03
	(f) Depreciation and amortization expense	68.14	67.43	56.21	135.56	82.80	216.84
	(g) Other expenses	323.24	170.01	153.72	493.25	198.27	626.54
	Total Expenses (IV)	8,513.92	4,982.57	3,389.79	13,496.49	4,538.98	14,212.40
V	**Profit before tax (III - IV)**	157.93	25.77	(79.60)	183.70	45.01	97.07
VI	**Tax expense:**						
	(1) Current tax	73.74	51.66	56.88	125.39	73.69	152.32
	(2) Deferred Tax	(18.72)	(8.53)	(18.86)	(27.24)	(32.58)	(75.40)
	(3) Prior Period Tax	-	-	-	-	-	(35.86)
	Total Tax Expense	55.02	43.13	38.02	98.15	41.11	41.06
VII	**Profit for the period (V-VI)**	102.92	(17.37)	(117.62)	85.55	3.90	56.01
	Profit for the period Attributable to						
	i. Equity Holder of Parent	125.21	25.98	(66.09)	151.19	55.43	160.37
	ii. Non Controlling Interest	(22.30)	(43.34)	(51.52)	(65.64)	(51.52)	(104.35)
VIII	**Other Comprehensive Income/(Loss)**						
	(i) Items that will not be reclassified to Profit and Loss						
	(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.68
	(b) Income tax effect on above	-	-	-	-	-	(0.17)
	(c) Equity instrument through other comprehensive income	(34.28)	16.78	(18.07)	(17.50)	(3.81)	(50.68)
	(d) Income tax effect on above	-	-	-	-	-	-
	Total Other Comprehensive Income / (Loss)	(34.28)	16.78	(18.07)	(17.50)	(3.81)	(50.17)
IX	**Total Comprehensive Income/(Loss) for the year (VII + VIII) (Comprising profit and other comprehensive income for the year)**	68.63	(0.58)	(135.69)	68.05	0.09	5.84
	Total Comprehensive Income/(Loss) Attributable to						
	i. Equity Holder of Parent	90.94	42.76	(84.17)	133.70	51.62	110.16
	ii. Non Controlling Interest	(22.30)	(43.34)	(51.52)	(65.64)	(51.52)	(104.32)
	Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	5,537.20	5,537.20	5,537.20	5,537.20	5,537.20	5,537.20
	Other Equity						
XI	**Earning per equity share**						
	(a) Basic	0.01	(0.00)	(0.02)	0.01	0.00	0.01
	(b) Diluted	0.01	(0.00)	(0.02)	0.01	0.00	0.01

Notes:

1.The unaudited financial results of the Group for the quarter ended September 30, 2026 and half year ended September 30, 2026 have been prepared in accordance with the Indian Accounting Standards("Indian Accounting Standards("Ind As')As Prescribed under section 133 of the Companies Act, 2013 as amended.

2. Segment Report has been annexed in Annexure 1.

3.The unaudited financial results of the Group for the quarter ended September 30, 2026 and half year ended September 30, 2026 have been reviewed by the audit committee on November 03, 2026 and thereafter Board of directors at their meeting held on November 03, 2026.

4. The results for the quarter ended September 30, 2026 are the balancing figures between in respect of the half year ended results as on September 30, 2026 and the published unaudited financial results for the quarter ended June 30, 2026. Similarly, The results for the quarter ended September 30, 2025 are the balancing figures between in respect of the half year ended results as on September 30, 2025 and the published unaudited financial results for the quarter ended June 30, 2025.

5. Assets and liabilities held for sale
During the meeting held on November 03, 2026, the Board of Directors approved a plan to sell its entire equity stake in its subsidiary, Clinigenome India Private Limited, which will result in loss of control over Clinigenome India Private Limited, all the assets and liabilities of B Limited have been classified as "Assets held for sale" and "Liabilities directly associated with assets held for sale" in the consolidated financial results as at September 30,2026, in accordance with Ind AS 105. The disposal group is measured at the lower of its carrying amount and fair value less costs to sell, and depreciation and amortisation on its non-current assets have ceased from the date of classification. No impairment loss has been recognised upon such classification for the period ended September 30, 2026.

6.Previous period figures have been regrouped/reclassified, as considered necessary, to conform with current period presentation, wherever applicable.

For and on Behalf of the Board of Directors of
Genpharmasec Limited

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN : 09629728

GENPHARMASEC LIMITED KANDIVALI (E) MUMBAI 400 101.

Place: Mumbai
Date: November 03, 2026

GENPHARMASEC LIMITED
CIN: L24231MH1992PLC323914
Statement of Consolidated Assets and Liabilities
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
ASSETS		
(1) Non-Current Assets		
(a) Plant Property and Equipments	1,513.58	2,131.02
(b) Right to Use Assets	84.77	181.32
(c) Intangible Assets	0.16	0.34
(d) Goodwill	1,811.79	1,811.79
(e) Financial Assets		
(i) Investment	140.82	158.31
(ii) Loans	719.37	698.82
(iii) Other Financial Assets	429.64	88.55
(f) Other Non Current Assets	606.13	441.12
(g) Deferred Tax Assets (Net)	214.68	251.60
(h) Non-Current Tax Assets (Net)	16.71	-
Total Non-Current Assets	**5,537.65**	**5,762.87**
(2) Current Assets		
(a) Inventories	1,354.54	1,387.53
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivable	2,731.37	2,927.10
(iii) Cash and Cash Equivalents	292.51	97.41
(iv) Bank Balances Other than above	250.00	909.99
(v) Loans	0.60	0.60
(vi) Other Financial Assets	109.89	96.82
(c) Current Tax Assets (net)	-	26.64
(d) Other Current Assets	2,458.76	2,606.38
Total Current Assets	**7,197.67**	**8,052.48**
Assets held for sale	**713.72**	**-**
TOTAL - ASSETS	**13,449.04**	**13,815.35**
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	5,537.20	5,537.20
(b) Other Equity	1,238.84	1,089.27
(c) Non- Controlling Interest	(127.62)	(61.98)
Total Equity	**6,648.42**	**6,564.49**
LIABILITIES		
1. Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	701.60	2,397.24
(ii) Lease Liabilities	64.79	136.77
(iii) Provisions	18.25	13.91
Total Non-Current Liabilities	**784.64**	**2,547.93**
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,595.13	900.45
(ii) Lease Liabilities	25.19	60.22
(iii) Trade Payables	-	-
(A)Total outstanding dues of micro and small enterprises	51.00	40.57
(B)Total outstanding dues of creditors other than micro and small enterprises	1,665.07	3,118.12
(iv) Other Financial Liabilities	368.84	292.76
(b) Short Term Provisions	3.10	2.67
(c) Current Tax Liabilities (net)	107.38	91.22
(d) Other Current Liabilities	2,083.00	196.93
	5,898.71	**5,972.11**
Liabilities directly associated with assets held for sale	**117.27**	**-**
TOTAL - EQUITY AND LIABILITIES	**13,449.04**	**13,449.04**

For and on Behalf of the Board of Directors of
Genpharmasec Limited

Sohan

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN : 09629728

GENPHARMASEC LIMITED KANDIVALI (E) MUMBAI 400 101

Place: Mumbai
Date: November 03, 2026

GENPHARMASEC LIMITED

CIN: L24231MH1992PLC323914

Statement of Consolidated Unaudited Cash Flow

(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	For the period ended September 30, 2026 (Unaudited)	For the period ended September 30, 2025 (Unaudited)
A) Cash Flow from Operating Activities		
Net Profit Before Tax	**183.70**	**45.01**
Adjustment for :		
Depreciation and Amortization	135.56	81.94
Expected Credit Loss	3.74	25.66
Interest Income other than interest on Bank Deposits	(30.30)	(105.05)
Interest on Bank Deposits	(39.51)	-
Finance Cost other than interest on lease liabilities	75.80	24.49
Interest on lease liabilities	8.30	10.17
Dividend Income	(0.01)	(0.01)
Balances Written Off	32.35	-
Provision for Gratuity	1.20	6.19
Creditors Written Back	(32.34)	-
Deferred Rent Income	(0.86)	-
Profit on derecognition/Modification of Liability	(1.84)	-
Foreign Currency Translation Reserve	15.88	-
Operating Profit before Working Capital Changes	**351.66**	**88.40**
Adjustment for		
Changes in Inventories	3.58	(1,142.77)
Changes in Trade Receivables	153.07	(1,007.89)
Changes in Other Non Current & Current Financial Assets	76.04	86.59
Changes in Other Current Assets	147.64	(187.86)
Changes in Other Non Current Assets	(166.42)	41.72
Changes in Trade Payables	(1,366.20)	3,101.70
Changes in Other Financial Liabilities	76.08	199.44
Changes in Other Current Liabilities	1,887.23	85.69
	1,162.69	**1,265.01**
Income Tax Paid (Net)	(109.76)	(147.21)
Net Cash Generated from Operating Activities	**1,052.93**	**1,117.80**
B) Cash Flow from Investing Activities		
Purchase of Fixed Assets	(8.63)	(54.46)
Investments made	-	(119.45)
Fixed Deposit Made (Net)	-	(857.03)
Loans given	-	(167.38)
Receipt against loan given	8.50	0.42
Interest Received	10.39	21.84
Dividend Received	0.01	0.01
Net Cash used in Investment Activities	**10.27**	**(1,176.05)**
C) Cash Flow from Financing Activities		
Proceeds from short term borrowings (Net)	694.68	25.54
Proceeds from of Long Term Borrowings	(1,695.64)	-
Payment of Lease liability	(40.06)	(35.24)
Finance charges paid	(75.80)	(24.49)
Net Cash generated/(used) in Financing Activities	**(1,116.82)**	**(34.19)**
D. Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	**(53.62)**	**(92.44)**
Cash & cash equivalents acquired pursuant to acquisition of subsidiary	-	**69.14**
E. Opening Cash & Cash Equivalents (Cash and Bank Balances)	97.41	527.14
Add: Fixed Deposit having maturity less than three months	250.00	-
Closing Cash & Cash Equivalents (D+E)	**293.79**	**503.84**

Note

The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of Cash Flow

For and on behalf of the Board of
Genpharmasec Limited

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN : 09629728

GENPHARMASEC LIMITED KANJURMARG (E) MUMBAI 400 101

Place: Mumbai
Date: November 03, 2026

GENPHARMASEC LIMITED
CIN: L24231MH1992PLC323914
"ANNEXURE - I"

Statement of Consolidated unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year ended September 30, 2026

(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
Pharmaceutical Trading	8,154.52	4,699.11	3,071.70	12,853.63	4,238.79	13,087.05
Laboratory Testing	-	-	41.05	-	78.29	100.47
Manufacturing & Processing	411.30	271.92	150.96	683.22	150.96	806.24
Unallocable	-	-	-	-	-	-
Total	**8,565.82**	**4,971.03**	**3,263.71**	**13,536.85**	**4,468.04**	**13,993.77**
Segment Results (Profit before tax and interest)						
Pharmaceutical Trading	282.04	219.96	145.93	502.00	324.18	703.05
Laboratory Testing	(39.93)	(29.20)	(37.57)	(69.14)	(78.96)	(158.87)
Manufacturing & Processing	(40.00)	(125.07)	(165.35)	(165.07)	(165.35)	(322.44)
Unallocable	-	-	(0.08)	-	(0.08)	(0.65)
Total	**202.11**	**65.68**	**(57.08)**	**267.79**	**79.79**	**221.09**
Less						
(i) Unallocated Finance Cost	(44.18)	(39.92)	(22.52)	(84.09)	(34.78)	(124.03)
(ii) Other unallowable expenditure net of unallowable income	-	-	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-	-	-
Profit Before Tax	**157.93**	**25.77**	**(79.60)**	**183.70**	**45.01**	**97.07**
Segment Assets						
Pharmaceutical Trading	7,699.17	9,915.53	8,445.12	7,699.17	8,445.12	6,189.42
Laboratory Testing	713.72	734.65	959.72	713.72	959.72	753.26
Manufacturing & Processing	5,036.15	4,978.17	2,982.77	5,036.15	2,982.77	2,992.08
Unallocated	-	-	11.89	-	11.89	3,880.58
Total	**13,449.04**	**15,628.35**	**12,399.50**	**13,449.04**	**12,399.50**	**13,815.34**
Segment Liabilities						
Pharmaceutical Trading	5,286.51	6,917.25	4,408.13	5,286.51	4,408.13	3,856.43
Laboratory Testing	117.27	791.60	820.97	117.27	820.97	136.85
Manufacturing & Processing	1,396.84	1,355.59	606.26	1,396.84	606.26	1,194.37
Un-Allocated	-		5.41	-	5.41	2,063.22
Total	**6,800.62**	**9,064.44**	**5,840.76**	**6,800.62**	**5,840.76**	**7,250.86**

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board of
Genpharmasec Limited

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN : 09629728

GENPHARMASEC LIMITED KANDIVALI (E) MUMBAI 400 101.

Place: Mumbai
Date: November 03, 2026

Date: 03.11.2026

To,
Board of Directors
Genpharmasec Limited
Office No. 104 & 105 (1st Floor),
Gundecha Industrial Premises Co-Operative Society Ltd.,
Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101

Subject: Resignation from the position of Company Secretary and Compliance Officer of the company.

Dear Sir,

This is to inform you that, I hereby tender my resignation from the position of Company Secretary and Compliance Officer of Genpharmasec Limited with effect from the closure of business hours of November 16, 2026 due to pursue other professional opportunities outside the organization.

I request the Board of Directors to kindly accept my resignation, acknowledge the receipt of this resignation letter and relieve me from my duties and responsibilities with effect from aforementioned date.

Furthermore, I hereby confirm that there are no other material reasons for my resignation other than those stated above.

I would request the company to file necessary filings, intimations and disclosures with the concerned authorities including Registrar of Companies (ROC) and Stock exchange(s), as may be required under applicable laws and regulations.

Thank you for the opportunities for professional and personal development that have been provided to me. I have enjoyed working for this Company and appreciate the support provided to me during my tenure with the company.

Thanking you,

Yours faithfully,

Hardik Makwana
Company Secretary
M. No.: A72702